Welcome to our dedicated page for Gentex SEC filings (Ticker: GNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gentex Corporation (NASDAQ: GNTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Gentex is a Michigan-incorporated technology company that supplies digital vision, connected-car, dimmable glass, fire protection, medical, biometric, and consumer electronics products to multiple industries, including automotive and aerospace.
Through this page, users can review current reports on Form 8-K, which Gentex uses to announce material events such as quarterly financial results. For example, the company files 8-K reports to furnish news releases detailing results of operations and financial condition for specific quarters, attaching those releases as exhibits. These documents help investors understand revenue by category, gross margin trends, operating expenses, and the impact of acquisitions like VOXX on consolidated results.
In addition to 8-Ks, investors typically consult annual reports on Form 10-K and quarterly reports on Form 10-Q for more comprehensive information on Gentex’s business, risk factors, segment performance, and capital allocation. Filings related to share repurchases, dividend declarations, and guidance updates can provide further insight into how Gentex manages its balance sheet and returns capital to shareholders.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify major developments, changes in guidance, and important risk disclosures. Real-time updates from EDGAR make it easier to track new Gentex filings as they appear, while access to historical reports supports deeper research into the company’s long-term performance and strategic direction.
A holder of GNTX common stock has filed a notice of proposed sale under Rule 144 for 9,024 shares, to be sold through Morgan Stanley Smith Barney LLC on or around 02/17/2026 on the NASDAQ, with an aggregate market value of $223,165.32.
The filing states that all of these shares were acquired on 02/16/2026 via vesting of 1,879 restricted stock units and 7,145 performance stock units granted by the issuer as compensation for services. Shares outstanding were 218,942,919 at the time referenced.
A shareholder of Gentex Corporation filed a notice of proposed sale under Rule 144 to sell 11,248 shares of common stock through Morgan Stanley Smith Barney on NASDAQ, with an approximate sale date of 02/17/2026 and an aggregate market value of $279,175.36.
The notice shows that these shares were acquired on 02/16/2026 via 2,332 restricted stock units vesting under a registered plan and 8,916 performance stock units, both paid for in cash. Gentex had 218,942,919 shares outstanding at the time, providing context for the size of the planned sale.
Wellington Management Group LLP and related entities report beneficial ownership of 2,300,392 Gentex Corporation common shares, representing about 1.05% of the class. All voting and dispositive power is shared, with no sole authority reported. The securities are held on behalf of Wellington investment advisory clients.
The filing notes Wellington’s stake is below 5% of Gentex’s outstanding common stock and that no individual client is known to hold more than 5% of the class. Wellington certifies the position is held in the ordinary course of business and not to change or influence control of Gentex.
Gentex Corporation filed a current report to make investors aware that it has released its latest financial results. The company issued a news release covering its fourth quarter and full year ended December 31, 2025, dated January 30, 2026.
The news release is provided as Exhibit 99.1 and is being furnished under the rules for results of operations and financial condition, rather than filed for liability purposes under Section 18 of the Exchange Act. The report is signed on behalf of Gentex by Kevin C. Nash, Vice President - Finance and Chief Financial Officer.
Gentex Corporation (GNTX) filed its Q3 2025 Form 10‑Q, reporting steady top‑line growth with net sales of $655,236,055, up from $608,525,777 a year ago. Quarterly net income was $100,967,910, and diluted EPS was $0.46.
For the first nine months, sales reached $1,889,867,355 with net income of $291,881,539. Operating cash flow was strong at $461,627,573, while the company invested in capacity and deals, including the April 1 consolidation of VOXX. Gentex recognized $8.4 million in other‑than‑temporary impairment charges on technology investments and increased its credit loss allowance by $4.8 million. The company amended its unsecured revolver to $350.0 million on October 2, 2025. It returned capital via dividends of $0.12 per share in Q3 and repurchased $230,450,683 of stock year‑to‑date. Cash and cash equivalents were $178,589,422 at quarter‑end, and shares outstanding were 218,942,919 as of October 24, 2025.
Gentex Corporation furnished an Item 2.02 Form 8‑K announcing financial results for the third quarter ended September 30, 2025, and attached a news release as Exhibit 99.1. The report is dated October 24, 2025.
The company stated that the information in this report and its exhibit is furnished and not deemed filed for purposes of Section 18 of the Exchange Act. The filing also lists Item 9.01 for the exhibit index, with the press release identified as Exhibit 99.1.
Kevin C. Nash, Chief Financial Officer and Director of Gentex Corporation (GNTX), reported a transaction dated 08/26/2025 affecting his holdings. The filing shows 865 shares disposed of Common Stock at a price of $28.28 per share. After the reported transaction, Mr. Nash beneficially owned 54,304 shares directly. The form includes an explanatory note stating the shares were purchased through the Gentex Corporation Employee Stock Purchase Plan, a Section 423(b) plan. The Form 4 was signed on behalf of Mr. Nash by a power of attorney on 08/27/2025. No derivative securities or additional transactions are reported in this filing.
Gentex reported consolidated net sales of $657.9 million for the quarter ended June 30, 2025, up 15% from $572.9 million a year earlier, driven largely by the April 1, 2025 acquisition of VOXX which contributed $78.8 million of revenue. Consolidated gross profit rose to $225.3 million, and consolidated income from operations was $118.5 million. Net income attributable to Gentex was $96.0 million (diluted EPS $0.43), versus $86.0 million (EPS $0.37) in the comparable quarter.
Cash and cash equivalents decreased to $119.8 million from $233.3 million at year-end 2024 after investing activity, acquisition payments and share repurchases. Operating cash flow provided $314.6 million in the six months ended June 30, 2025. The company completed the VOXX acquisition for approximately $148.3 million in cash (total consideration, net $187.7 million including fair value of prior holdings) and made other biometric-related acquisitions; integration costs, severance and a $6.2 million impairment were recorded in the quarter.